{
  "id": 8857955,
  "title": "Beacon says gene therapy succeeds in key trial of rare eye disease XLRP",
  "url": "https://urgent.news/2026/09/21/beacon-says-gene-therapy-succeeds-in-key-trial-of-rare-eye-disease",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-21T06:00:58.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/beacon-says-gene-therapy-succeeds-in-key-trial-of-rare-eye-disease-xlrp/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Beacon Therapeutics has succeeded in a genetic eye disease where large drugmakers including Johnson & Johnson and Biogen have failed. On Monday, Beacon said its gene therapy for X-linked retinitis pigmentosa (XLRP) passed a Phase ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Syncona jumps 6% after Beacon gene therapy trial success",
        "url": "https://urgent.news/2026/09/21/syncona-jumps-6-after-beacon-gene-therapy-trial-success",
        "published": "2026-09-21T09:00:41.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}